$\square$ 

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

Iſ

subject to 5 ee

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	-								
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

1. Name and Address of Reporting Person <sup>*</sup> ANDO DALE G			2. Issuer Name and Ticker or Trading Symbol <u>SANGAMO BIOSCIENCES INC</u> [ SGMO ]		tionship of Reporting Pers all applicable) Director	n(s) to Issuer 10% Owner	
(Last) (First) (Middle) C/O SANGAMO BIOSCIENCES INC. POINT RICHMOND TECH CNTR, 501 CANA BLVD		S INC.	3. Date of Earliest Transaction (Month/Day/Year) 02/05/2015	x	Officer (give title below) VP, Therapeutic De	Other (specify below) v. & CMO	
SLVD (Street) RICHMOND (City)	CA (State)	94804 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	idual or Joint/Group Filing Form filed by One Repo Form filed by More thar Person	orting Person	

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)				5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1130.4)
Common Stock	02/05/2015		М		11,798	A	\$6.82	107,174 <sup>(2)(3)</sup>	D	
Common Stock	02/05/2015		М		3,202	A	\$3.45	110,376 <sup>(2)(3)</sup>	D	
Common Stock	02/05/2015		<b>S</b> <sup>(1)</sup>		15,000	D	<b>\$12.93</b> <sup>(4)</sup>	95,376 <sup>(2)(3)</sup>	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of Deri Secu Acq (A) ( Disp of (E	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		te of Securities		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Employee Stock Option (Right to Buy)	\$6.82	02/05/2015		М			11,798	(5)	12/12/2016	Common Stock	11,798	\$0	0	D	
Employee Stock Option (Right to Buy)	\$3.45	02/05/2015		М			3,202	(5)	12/09/2018	Common Stock	3,202	\$0	110,798	D	

## Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to the Rule 10b5-1 trading plan adopted by the Reporting Person on June 23, 2014.

2. Includes 11,666, 15,333 and 25,000 shares subject to RSUs granted on December 6, 2012, December 12, 2013 AND December 11, 2014 respectively, which will be issued as such units vest in accordance with their terms.

3. Includes 1,277 shares acquired by the Reporting Person on October 31, 2014 under the Issuer's Employee Stock Purchase Plan.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$12.61 to \$13.12, inclusive. The Reporting Person undertakes to provide to Sangamo BioSciences, Inc., any security holder of Sangamo BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

5. All shares underlying this option are vested and immediately exercisable.

Remarks:

<u>/s/ Florence Tam, attorney-in-</u><u>0</u> fact

<u>02/06/2015</u> Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.